Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
Terminated
Oxnard Foundation
Early Phase 1
2013-06-01
This study will investigate the possibility of using the drug thioridazine (also called
Mellaril) to increase the number of certain types of cells moving from the bone marrow to the
circulation in a group of healthy humans. The types of cells we hope to collect are called
CD34+ progenitor, or stem cells. These cells can be used in the laboratory to better
understand a number of diseases and suggest new strategies for therapy. Perhaps the most
important potential application of human stem cells is the generation of cells and tissues
that could be used for cell-based therapies, as a renewable source of replacement cells and
tissues to treat diseases including Alzheimer's diseases, spinal cord injury, stroke, burns,
heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.
Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
Terminated
New Mexico Cancer Care Alliance
Early Phase 1
2013-06-01
This study will investigate the possibility of using the drug thioridazine (also called
Mellaril) to increase the number of certain types of cells moving from the bone marrow to the
circulation in a group of healthy humans. The types of cells we hope to collect are called
CD34+ progenitor, or stem cells. These cells can be used in the laboratory to better
understand a number of diseases and suggest new strategies for therapy. Perhaps the most
important potential application of human stem cells is the generation of cells and tissues
that could be used for cell-based therapies, as a renewable source of replacement cells and
tissues to treat diseases including Alzheimer's diseases, spinal cord injury, stroke, burns,
heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
